16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
October 2023 in “Indian journal of ophthalmology. Case reports” A woman lost vision in one eye after a forehead injection, but prompt treatment led to partial vision recovery.
April 2021 in “Journal of Investigative Dermatology” 6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
4 citations
,
November 2024 in “Journal of Advanced Research” Targeting NMMHC IIA may help treat blood-brain barrier damage.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
16 citations
,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology” 6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
January 2024 in “Acta dermato-venereologica”
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
4 citations
,
August 2024 in “International Journal of Molecular Sciences” EBGS reduces platelet adhesion, potentially helping prevent blood clots.
April 2025 in “International Journal of Dermatology” Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.